A study to determine the feasibility of molecular selection of therapy in patients with metastatic colorectal cancer

确定转移性结直肠癌患者分子治疗选择可行性的研究

• 批准号: G0701770/1
• 负责人: TIMOTHY MAUGHAN
• 金额: $ 54.27万
• 依托单位: CARDIFF UNIVERSITY
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2008
• 资助国家: 英国
• 起止时间: 2008 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0701770%2F1
• 关键词: study; determine; feasibility; molecular; selection

When cancer of the bowel is not completely removable by surgery, or when the cancer has spread to somewhere else in the body, chemotherapy, a form of drug treatment which aims to kill cancer cells, may be given. Usually, the specific chemotherapy that is offered to a patient is chosen on how well it works on average in patients.There are in all five types of medicine which have been shown to work in colorectal cancer. The most commonly used chemotherapy for bowel cancer is called ?5FU?, which is also known as ?fluorouracil?. Our previous study (called FOCUS) showed that the combination of 5FU and irinotecan, a new drug, gave the best results, so this is being used as the standard treatment in this research. This will allow us to compare the usual treatment against different combinations of medicines.In recent years two new treatments have been developed which are not standard chemotherapy. These are called cetuximab and bevacizumab (monoclonal antibodies), which specifically act on special proteins associated with the growth of the cancer. In this trial we will be comparing ways of using all these drugs in the best way by testing the treatments that we think will work best for the type of tumour that participants have, according to molecular testing. These tests will identify the cancer as one of four ?types?.For each type of cancer, we will be comparing the effects of different treatment plans. Patients will be randomly allocated to three different treatments to discover which is best; one is the usual course of treatment that would be offered. The other two plans are those which the tumour sample tests suggest might be better than the usual treatment for that particular type of bowel cancer. The treatment is given on a regular basis, every two weeks and continues for at least six months, provided the cancer remains under good control and there are no unpleasant side effects.Participants of the trial will also be asked for permission to use the tumour sample they have already given in future scientific studies. Specifically, we will look at other possible tests of proteins or of genes that may predict which treatment would work best for individual patients. In addition, we will ask participants for a blood sample for further research purposes.

当肠癌不能通过手术完全切除时，或者当癌症已经扩散到身体的其他地方时，可以给予化疗，这是一种旨在杀死癌细胞的药物治疗形式。通常，提供给患者的特定化疗是根据患者的平均效果来选择的。所有五种类型的药物都已被证明对结直肠癌有效。肠癌最常用的化疗叫什么？5FU？，也被称为？氟尿嘧啶？ 我们之前的研究（称为FOCUS）表明，5 FU和伊立替康（一种新药）的组合效果最好，因此将其用作本研究的标准治疗。这将使我们能够比较常规治疗与不同的药物组合。近年来，已经开发了两种新的治疗方法，而不是标准的化疗。这些被称为西妥昔单抗和贝伐单抗（单克隆抗体），它们特异性地作用于与癌症生长相关的特殊蛋白质。在这项试验中，我们将通过测试我们认为最适合参与者所患肿瘤类型的治疗方法，比较以最佳方式使用所有这些药物的方法。这些测试将确定癌症的四个之一？类型？对于每种类型的癌症，我们将比较不同治疗计划的效果。患者将被随机分配到三种不同的治疗，以发现哪种是最好的;一个是通常的治疗过程，将提供。另外两个计划是肿瘤样本测试表明可能比特定类型肠癌的常规治疗更好的计划。这项治疗每两周进行一次，持续至少六个月，前提是癌症得到良好控制，并且没有令人不快的副作用。试验参与者还将被要求允许在未来的科学研究中使用他们已经提供的肿瘤样本。具体来说，我们将研究其他可能的蛋白质或基因测试，这些测试可以预测哪种治疗方法对个体患者最有效。此外，我们将要求参与者提供血液样本以供进一步研究。